Related Experiment Video

Updated: Jul 5, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects

Alessandro Sciarra1, Vincenzo Gentile, Stefano Salciccia

  • 1Department U Bracci, University Sapienza, Rome, Italy. sciarrajr@hotmail.com

Reviews on Recent Clinical Trials
|May 14, 2008
PubMed
Abstract

Insights

Anti-angiogenic targeted therapies, including Sunitinib and Sorafenib, show effectiveness in treating advanced renal cell carcinoma (RCC), particularly in metastatic cases. These treatments are revolutionizing clinical approaches for advanced RCC.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) is genetically linked to angiogenesis factors, notably vascular endothelial growth factor (VEGF).
  • Targeted therapies aim to inhibit key signaling pathways involved in tumor growth and vascularization.

Purpose of the Study:

  • To review the rationale and efficacy of anti-angiogenic targeted therapies in advanced renal cell carcinoma (RCC).
  • To summarize the current landscape of targeted agents like Sunitinib and Sorafenib for advanced RCC treatment.

Main Methods:

  • A comprehensive review of international literature was conducted using PubMed.
  • Analysis focused on clinical trials and genetic links related to angiogenesis in RCC.

Main Results:

  • Sunitinib and Sorafenib are multi-target tyrosine kinase inhibitors effective against advanced RCC, especially in cytokine-refractory metastatic disease.
  • These agents demonstrated acceptable toxicity profiles in Phase I trials and survival benefits in Phase II/III trials.
  • Optimal use may involve cytoreductive nephrectomy prior to systemic therapy and further research into predictive biomarkers and combination strategies.

Conclusions:

  • FDA-approved targeted therapies, Sunitinib and Sorafenib, represent a significant advancement in managing advanced renal cell carcinoma.
  • These agents are transforming the clinical approach to advanced RCC, offering new hope for patients.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...